Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M508234200 on August 17, 2005

J. Biol. Chem., Vol. 280, Issue 42, 35760-35766, October 21, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/42/35760    most recent
M508234200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Balabanian, K.
Right arrow Articles by Bachelerie, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Balabanian, K.
Right arrow Articles by Bachelerie, F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Chemokine SDF-1/CXCL12 Binds to and Signals through the Orphan Receptor RDC1 in T Lymphocytes*

Karl Balabanian{ddagger}12, Bernard Lagane{ddagger}13, Simona Infantino§, Ken Y. C. Chow{ddagger}4, Julie Harriague{ddagger}3, Barbara Moepps¶, Fernando Arenzana-Seisdedos{ddagger}, Marcus Thelen§, and Françoise Bachelerie{ddagger}5

From the {ddagger}Unité d'Immunologie Virale, Institut Pasteur, 75015 Paris, France, the §Institute for Research in Biomedicine, CH-6500 Bellinzona, Switzerland, and the Department of Pharmacology and Toxicology, University of Ulm, D-89081 Ulm, Germany

Received for publication, July 27, 2005 , and in revised form, August 11, 2005.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS AND DISCUSSION
 REFERENCES
 
Combined phylogenetic and chromosomal location studies suggest that the orphan receptor RDC1 is related to CXC chemokine receptors. RDC1 provides a co-receptor function for a restricted number of human immunodeficiency virus (HIV) isolates, in particular for the CXCR4-using HIV-2 ROD strain. Here we show that CXCL12, the only known natural ligand for CXCR4, binds to and signals through RDC1. We demonstrate that RDC1 is expressed in T lymphocytes and that CXCL12-promoted chemotaxis is inhibited by an anti-RDC1 monoclonal antibody. Concomitant blockade of RDC1 and CXCR4 produced additive inhibitory effects in CXCL12-induced T cell migration. Furthermore, we provide evidence that interaction of CXCL12 with RDC1 is specific, saturable, and of high affinity (apparent KD {approx} 0.4 nM). In CXCR4-negative cells expressing RDC1, CXCL12 promotes internalization of the receptor and chemotactic signals through RDC1. Collectively, our data indicate that RDC1, which we propose to rename as CXCR7, is a receptor for CXCL12.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS AND DISCUSSION
 REFERENCES
 
In concert with surface adhesion molecules, chemokines are secreted proteins that govern the migration of distinct leukocyte subsets to sites of inflammation and to their specific niches in lymphoid organs (1-3). Two main subfamilies are distinguished according to the position of the first two cysteines, which are separated by one amino acid (CXC chemokines) or are adjacent (CC chemokines) (4, 5). Chemokines mediate their functions by binding to chemokine receptors (CKRs),6 which belong to the large family of heptahelical G protein-coupled receptors. CKRs share >20% sequence identity, and their interactions with chemokines are highly promiscuous and often redundant (6).

The orphan receptor RDC1, which was originally cloned on the basis of its homology with conserved domains of G protein-coupled receptors (7, 8), was primarily believed to act as a receptor for vasointestinal peptide (9), a possibility later dismissed (10, 11). In fact, combined phylogenetic and chromosomal location studies suggested that RDC1 represents a CKR structurally close to CXC receptors (12-14), pointing to CXC chemokines as potential ligands. The RDC1 gene maps to mouse chromosome 1 and human chromosome 2, where the genes encoding CXCR1, CXCR2, and CXCR4 are localized (12,15,16, 48). Like CXCR4, the only known receptor for the chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12, RDC1 can serve as coreceptor for certain genetically divergent human immunodeficiency virus (HIV) and simian immunodeficiency virus strains, in particular for the HIV-2 ROD, an X4-tropic isolate (17). This suggests that both CKRs interact with a conserved domain of the viral envelope glycoprotein gp120, which displays some similarities with chemokines, for binding to CKRs and signaling in T cells (18, 19). Here we provide evidence that RDC1 and CXCR4 also share CXCL12 as a natural ligand.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS AND DISCUSSION
 REFERENCES
 
Antibodies, Reagents, and Cells—FITC-conjugated anti-human CD3 (clone SK7, IgG1) and PE-conjugated anti-human CXCR4 (clone 12G5, IgG2a) monoclonal antibodies (mAbs) were from BD Biosciences. The generation of the mouse anti-human RDC1 mAb (clone 9C4, IgG1) is described elsewhere.7 Briefly, the N terminus of human RDC1 (first 27 amino acids) was fused with carrier proteins, and the recombinant fusion proteins were used for immunization of mice. Positive hybridomas were screened by enzyme-linked immunosorbent assay using a synthetic peptide (DYSEPGNFSDISWPC) corresponding to amino acids 7-21 of RDC1, designated here as RDC1-(7-21) (see Fig. 2A). The binding of unconjugated anti-RDC1 and anti-CXCR4 (12G5, BD Biosciences) mAbs was revealed using a FITC- or a PE-conjugated goat anti-mouse F(ab')2 Ab (Dako, Glostrup, Denmark) and analyzed on a FACSCalibur flow cytometer (BD Biosciences) with the CellQuest software. CXCL12, CXCL12-(4-67), and the C-terminal end biotinylated CXCL12 (biot-CXCL12) were kindly provided by Dr. F. Baleux (Institut Pasteur, Paris, France). Interleukin-8/CXCL8, BCA-1/CXCL13 and 6Ckine/CCL21 were from R&D Systems (Minneapolis, MN). PBLs were isolated from heparin-treated blood samples of healthy volunteers as described (20) and cultured overnight in RPMI 1640 medium supplemented with 10% fetal calf serum, 10 mM HEPES, penicillin (100 units/ml), and streptomycin (100 µg/ml) (complete RPMI medium). Dermal fibroblasts, isolated and expanded from healthy skin biopsies (20), and the HEK 293T (American Type Culture Collection, Manassas, VA) cell line were maintained in complete Dulbecco's modified Eagle's medium. The A0.01 T-cell (from Dr. H. T. He, Centre d'Immunologie de Luminy, Marseille, France) and 300.19 murine pre-B cell lines were cultured in complete RPMI medium.

RDC1 and CXCR4 Expression Vectors and Functional Assays—The human RDC1, {Delta}RDC1, and CXCR4 cDNAs were cloned into the pTRIP vector (kindly provided by Dr P. Charneau, Institut Pasteur, Paris, France) and expressed in cells as specified in the legends to Figs. 2, 3, 4, 5. Briefly, transient expression was achieved either by the calcium phosphate-DNA co-precipitation method or by using NucleofectorTM technology (Amaxa Biosystems, Cologne, Germany), whereas stable expression was obtained following a lentiviral-based strategy as described (20) or by electroporation with 20 µg of linearized pcDNA3 containing RDC1 and selection with G418 (Sigma-Aldrich). The {Delta}RDC1 product was engineered by polymerase chain reaction and lacks the last C-terminal 39 residues (325stop). Competition assays of mAbs with chemokines or RDC1-(7-21) for binding to CKRs were adapted from (21). Briefly, competition of mAb (used at 2 or 5 µg/ml) binding by chemokines or RDC1-(7-21) was performed at 4 °C for 90 min in PBS containing 1% bovine serum albumin, 0.2% {gamma}Fc, and 0.1% NaN3. Bound mAbs in treated cells were quantified by flow cytometry as follows: [receptor geometric mean fluorescence intensity (MFI) of treated cells/receptor geometric MFI of untreated cells] x 100. Specific binding of CXCL12 to RDC1 was evaluated using the biot-CXCL12 in A0.01 T cells that lack endogenous RDC1 and CXCR4 at both mRNA (data not shown) and protein (see Figs. 2B and 5A) levels. These cells also lack cell surface heparan sulfates that are known to bind CXCL12. For saturation binding experiments, RDC1-expressing A0.01 cells (2.5 x 105) were maintained at room temperature for 90 min in binding buffer (PBS containing 0.2% bovine serum albumin and 0.1% NaN3) in the presence of increasing concentrations of biot-CXCL12. Following a washing step with ice-cold binding buffer, specifically bound biot-CXCL12 was subsequently revealed by incubating cells at 4 °C with 1 µg/ml streptavidin (SAv)-PE conjugate (BD Biosciences) in binding buffer for 20 min. Cells were then washed once and fixed in PBS containing 2% paraformaldehyde. Results were analyzed by flow cytometry. Specific binding was estimated by subtracting from the total binding the nonspecific binding determined either in the presence of unlabeled CXCL12 at 10-6 M (in RDC1-expressing cells) or following the binding of biot-CXCL12 to parental cells. For competition experiments, 7.5 x 10-10 M biot-CXCL12 was used as the tracer in the presence of increasing concentrations of untagged CXCL12. Binding parameters (KD and IC50) were determined with the Prism software (GraphPad Software Inc., San Diego, CA) using non-linear regressions applied to one-site models. Ki values were deduced according to the Cheng and Prusoff equation Ki = [IC50/(1 + (L/KD))], where L is the concentration of biot-CXCL12 used in competition binding experiments. Receptor internalization and chemotaxis assays were performed as described (20). Statistical analyses consisted of unpaired two-tailed Student's t tests and were conducted with the Prism software.



View larger version (38K):
[in this window]
[in a new window]
  		FIGURE 1.
Functional expression of RDC1 in T lymphocytes. A, upper sections, PBLs were stained with 10 µg/ml anti-RDC1 or anti-CXCR4 mAb followed by Texas Red-conjugated horse anti-mouse Ab and then labeled with a FITC-conjugated anti-CD3 mAb. Lower sections, PBLs were stained at 4 °C with 2 µg/ml specific mAb for RDC1 or CXCR4 in the absence (-) or presence (+) of 10 µM CXCL12 and then incubated with a FITC-conjugated horse anti-mouse Ab. Images were taken with structured illumination microscopy. No RDC1 or CXCR4 labeling was detected when PBLs were incubated with isotype control Abs (data not shown). Typical receptor fluorescence, 4',6-diamidino-2-phenylindole (DAPI)-positive nuclei (blue, lower panels), and differential interference contrast images are shown for 3-5 representative cells. Cells (n > 100) from two independent donors were analyzed. B, chemotaxis of PBLs was determined using a Transwell system in response to 30 nM CXCL12 or 60 nM CCL21 after 90 min of incubation in the presence (+) or absence (-) of anti-RDC1 and/or anti-CXCR4 mAbs. Chemokines were added to the lower chamber only, whereas mAbs were added to both chambers. Transmigrated cells recovered in the lower chamber were stained with an anti-CD3 mAb and counted by flow cytometry. Results (mean ± S.E.) are from three independent experiments and are expressed as percentage of input CD3+ T cells that migrated to the lower chamber. The fraction of CD3+ T cells migrating in response to CXCL12 was not modulated in the presence of the mouse isotype control Abs (65.9% ± 14.5% and 72.3% ± 9.0%, for IgG2a and IgG1, respectively).

 



View larger version (39K):
[in this window]
[in a new window]
  		FIGURE 2.
CXCL12 competes for binding of the 9C4 mAb to RDC1. A, alignment of the amino acid sequences of human RDC1 and CXCR4. Amino acid residues with identity (*), high similarity (:), and moderate similarity (.) are marked. Transmembrane domains are unlabeled, whereas intracellular and extracellular domains are highlighted in blue and red, respectively. A synthetic peptide (framed residues, RDC1-(7-21)) was used to screen hybridomas producing anti-RDC1 mAbs. B, RDC1-(7-21) prevents binding of the 9C4 mAb to RDC1. Left section, cell surface expression level of CXCR4 in A0.01 T-cells expressing the receptor after transduction was determined by flow cytometry using the 12G5 anti-CXCR4 mAb (12G5, red histogram). No labeling was detected using the corresponding isotype-matched control Ab (CTRL; gray histogram) or the anti-RDC1 9C4 mAb (green histogram). Right section, binding of the 9C4 mAb to RDC1 in A0.01 T-cells expressing the receptor after transduction is shown in the absence (9C4 untreated; red histogram) or presence of 10-7 M (dotted histogram) or 10-5 M (blue histogram) of RDC1-(7-21). No labeling was detected using the corresponding isotype-matched control Ab (CTRL; gray histogram) or the anti-CXCR4 12G5 mAb (data not shown), and binding of the 9C4 mAb was not affected by pre-incubating cells with an excess of RDC1-(7-21) (data not shown). C, HEK 293T cells expressing CXCR4 or RDC1 were generated by the calcium phosphate-DNA co-precipitation method and were assessed for the binding of the 9C4 or 12G5 mAb in the absence (untreated; red histogram) or presence (blue histogram) of 10-5 M CXCL12. Nonspecific binding was assessed after incubation of cells with the corresponding isotype-matched control Ab (gray histograms) or in the presence of the anti-RDC1 9C4 (in CXCR4-expressing cells; left section, green histogram) or anti-CXCR4 12G5 (in RDC1-expressing cells; right section, green histogram) mAb. Representative experiments of three independent determinations are shown. D, different concentrations of the chemokines (CK) CXCL12 and CXCL12-(4-67) were tested for their ability to compete with the binding of the 12G5 anti-CXCR4 (left section) or 9C4 anti-RDC1 (right section) mAb. Values are normalized for binding in the absence of CK (arbitrarily set at 100%; open bars) and represent means ± S.E. of three independent determinations.

 
Immunofluorescence—PBLs (2 x 105) were plated in RPMI medium supplemented with 1% bovine serum albumin and 20 mM HEPES onto polylysine-coated glass coverslips for 3 h at 37 °C and fixed in PBS with 4% paraformaldehyde. Cells were stained at room temperature with the anti-CXCR4 or anti-RDC1 mAb (10 µg/ml) for 30 min followed by FITC- or Texas Red-conjugated horse anti-mouse Ab (Vector Laboratories, Burlingame, CA). After three washes with PBS, cells were incubated with the FITC-conjugated anti-human CD3 mAb and finally mounted in Vectashield medium containing 4',6-diamidino-2-phenylindole (Vector Laboratories). For competitive experiments, cells were incubated at 4 °C with a mAb to CXCR4 or RDC1 (2 µg/ml) in the presence of 10 µM CXCL12. Fluorescence was imaged on a Zeiss microscope (Oberkochen, Germany) using a Plan Apochromat 100x, 1.4 oil immersion objective. Images were collected with a cooled charge-coupled device camera (Axiocam MRm), piloted by Axiovision imaging software (Zeiss). Optical sectioning was performed according to the structured illumination principle using the ApoTome system (Zeiss).


   RESULTS AND DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS AND DISCUSSION
REFERENCES
 
CXCL12-induced Chemotaxis of T lymphocytes Is Inhibited by an Anti-RDC1 mAb—Like CXCR4, the RDC1 gene is ubiquitously expressed in non-hematopoietic and hematopoietic tissues, and its mRNA is found in brain, heart, kidney, spleen, and PBLs (7, 17, 22). We investigated by immunofluorescence whether RDC1 is expressed in leukocytes using a mAb raised against human RDC1 (9C4). Leukocytes including CD3+ T lymphocytes (Fig. 1A) were stained either with the 9C4 anti-RDC1 mAb or 12G5 mAb, which recognizes an epitope in the second extracellular loop of CXCR4 (23-25). As expected, the concomitant addition of 10 µM CXCL12 abolished staining of CXCR4 with mAb 12G5. Interestingly, a molar excess of CXCL12 also prevented the 9C4 mAb from binding to T lymphocytes (Fig. 1A, lower sections). As cell migration features chemokine responses, we asked whether the 9C4 mAb could interfere with the CXCL12-stimulated chemotaxis of T lymphocytes. The chemotactic effect of 30 nM CXCL12 was inhibited by 40-50% in the presence of the 9C4 anti-RDC1 mAb or the 12G5 anti-CXCR4 mAb (10 µg/ml). When added together, both mAbs produced an additive inhibitory effect that extends up to 70% of the CXCL12-induced chemotaxis (Fig. 1B). By contrast, migration of lymphocytes in response to CCL21 (Fig. 1B) or CXCL13 (data not shown) was not affected by the addition of anti-RDC1 and anti-CXCR4 mAbs. These findings suggest that RDC1 is expressed at the surface of T lymphocytes and contributes to cell migration toward the CXCL12 gradient. However, the physiological role of RDC1 in T cell migration remains to be determined. Interestingly, CXCL12 displaces the binding of the anti-RDC1 mAb, which reacts with the N terminus of RDC1. Sequence alignment reveals that the N termini of CXCR4 and RDC1 display amino acid similarities and encompass acidic and aromatic residues (Fig. 2A) that are known to be critical for CXCR4 to bind human immunodeficiency virus gp120 and CXCL12 (26, 27). These findings suggest that CXCL12 interacts with the N terminus of RDC1.



View larger version (29K):
[in this window]
[in a new window]
  		FIGURE 3.
RDC1 is a high affinity receptor for CXCL12. A, direct interaction of biot-CXCL12 at the indicated concentrations to RDC1-transduced A0.01 T-cells was revealed by flow cytometry after addition of the SAv-PE conjugate at 1 µg/ml. Binding of SAv-PE alone to RDC1-expressing cells displayed marginal signals (gray histogram). B, saturation binding curve of biot-CXCL12 to RDC1-expressing cells is shown (open circles). Data, which represent geometric mean fluorescence intensity (MFI; expressed in arbitrary units (A. U.)) of SAv-PE bound to biot-CXCL12, are duplicated determinations from a representative experiment of two carried out independently. Nonspecific binding was determined in the presence of CXCL12 at 10-6 M (filled circles) or by measuring the binding of biot-CXCL12 to parental cells (triangles). C, a representative experiment showing concentration-dependent inhibition of 7.5 x 10-10 M biot-CXCL12 binding to RDC1-expressing cells by untagged CXCL12 determined by flow cytometry following SAV-PE staining. Results in panel D, carried out as in panel C, represent duplicated determinations from two independent experiments and are normalized for specific binding performed in the absence of competitor (100%; untreated).

 
CXCL12 Binds to RDC1—To confirm that the 9C4 mAb specifically recognizes RDC1, we first assessed whether the synthetic peptide RDC1-(7-21), which encompasses the epitope recognized by the 9C4 mAb, prevents binding of the mAb to the receptor. In A0.01 cells that lack endogenous expression of RDC1 and CXCR4, ectopic expression of RDC1 restored binding of the 9C4 mAb (Fig. 2B, right section, red histogram and Fig. 5A, right section) but not that of the anti-CXCR4 12G5 mAb (data not shown and Fig. 5A). Conversely, ectopic expression of CXCR4 promoted binding of the 12G5 mAb but not that of the anti-RDC1 9C4 mAb (Fig. 2B, left section, and see Fig. 5A, left section). When pre-incubated with RDC1-(7-21), the 9C4 mAb (5 µg/ml) was found to be impaired in its ability to recognize RDC1 in a dose-dependent manner (Fig. 2B, right section). We further evidenced that the 9C4 anti-RDC1 mAb bound to HEK 293T cells expressing the receptor (Fig. 2C, right section, red histogram) but not to the parental cells (data not shown) or to CXCR4-expressing (Fig. 2C, left section, green histogram) or CCR5-expressing (data not shown) cells. Conversely, the anti-CXCR4 12G5 (Fig. 2C, right section) or anti-CCR5 2D7 (data not shown) mAb did not label cells that expressed RDC1 alone. These findings indicate that the 9C4 mAb specifically recognizes RDC1. We then investigated the interaction between CXCL12 and RDC1 by assessing the ability of the chemokine to compete with the binding of the 9C4 mAb to RDC1. CXCL12 displaced the 9C4 as well as the 12G5 mAbs used at 2 µg/ml from binding to their respective receptors in a dose-dependent manner (Fig. 2, C-D). In contrast, CXCL12 did not modulate the binding of the anti-CCR5 mAb 2D7 on CCR5-expressing HEK 293T cells, and macrophage inflammatory protein-1{beta}/CCL4 did not prevent binding of mAbs to RDC1 or CXCR4 (data not shown). Truncation of the N terminus of CXCL12, which occurs upon cleavage by proteases, results in analogs that display reduced affinity for CXCR4 and a limited ability to trigger intracellular signaling (5, 27, 28). CXCL120-(4-67), which lacks the first three Lys1-Pro2-Val3 residues, displaced binding of the mAb 12G5 to CXCR4, but less efficiently than full-length CXCL12 did (Fig. 2D, left section). This CXCL12 derivative also moderately competes for the binding of the 9C4 mAb to RDC1 (Fig. 2D, right section), thus providing evidence of the involvement of the N terminus of CXCL12 in the binding to RDC1. To directly assess binding of CXCL12 to RDC1, we performed binding experiments using biot-CXCL12 (Fig. 3). The binding of biot-CXCL12 to cells expressing RDC1 was revealed with the SAv-PE conjugate and then quantitated by flow cytometry (Fig. 3, A and C). We found that binding of biot-CXCL12 to RDC1-expressing A0.01 cells was specific, dose-dependent, saturable, and of high-affinity (apparent KD = 0.4 ± 0.1 nM; Fig. 3, A and B). This affinity is approximately one order of magnitude higher than that estimated for CXCR4 (27). Nonspecific binding of biot-CXCL12 assessed either in A0.01 parental cells or in the presence of CXCL12 at 10-6 M was found to be minimal (Fig. 3B). When added at increasing concentrations, untagged CXCL12 displaced binding of 7.5 x 10-10 M biot-CXCL12 to RDC1-expressing A0.01 cells in a dose-dependent manner with IC50 = 5 ± 1.8 nM (apparent Ki = 1.8 ± 0.7 nM; Fig. 3, C and D). Overall, this demonstrates that RDC1 is a high affinity receptor for CXCL12.



View larger version (27K):
[in this window]
[in a new window]
  		FIGURE 4.
RDC1 is down-regulated in response to CXCL12. A, RDC1 cell surface expression was determined in electroporated 300.19 pre-B cells stably expressing the receptor by flow cytometry using the anti-RDC1 mAb (gray histogram) and the IgG1 control mAb (empty histogram). B, 300.19 pre-B cells were incubated for 45 min at 37 °C with the indicated concentrations of CXCL12 or left untreated and stained with the anti-RDC1 mAb (empty histograms) or the IgG1 control mAb (gray histograms). C, cell surface expressions of CXCR4, RDC1, and {Delta}RDC1 in nucleoporated dermal fibroblasts were determined by flow cytometry using the anti-CXCR4 or the anti-RDC1 mAb (empty histograms) or the corresponding isotype-matched control Ab (gray histograms). D, receptor expression levels in untreated (UNT; open bar) or treated with 2 x 10-7 M CXCL12 for 45 min at 37 °C are shown. Results are representative from two independent experiments performed in duplicate and indicate the amount of receptors that remains at the cell surface after incubation with CXCL12. 100% corresponds to receptor expression at the surface of cells incubated in medium alone.

 
CXCL12 Induces Down-regulation of RDC1—Receptor internalization is a widely described process that occurs upon chemokine stimulation (29). We thus investigated CXCL12-induced internalization of RDC1. Treatment of pre-B 300.19 cells expressing human RDC1 with increasing concentrations of CXCL12 induced a dose-dependent internalization of RDC1 (Fig. 4, A and B). Similarly, 2 x 10-7 M CXCL12 induced down-regulation of RDC1 expressed on dermal fibroblasts (Fig. 4, C and D) or on Chinese hamster ovary K1 or A0.01 cells (data not shown). By contrast, RDC1 was not internalized in response to two other CXC chemokines, CXCL8 and CXCL13 (data not shown). Agonist-induced CKR internalization generally relies on the phosphorylation of C-terminal Ser/Thr residues that, in turn, promotes binding of {beta}-arrestins for targeting to clathrin-coated pits (30). The C-terminal sequence of RDC1 contains multiple Ser/Thr residues (Fig. 2A) that could serve as structural determinants for receptor internalization. Fig. 4D shows that truncation of the RDC1 C terminus ({Delta}RDC1) abolished CXCL12-induced internalization, indicating that endocytosis requires the integrity of this domain. These results support the view that Ser/Thr residues of the RDC1 C terminus are subjected to phosphorylation by second messenger-dependent kinases and/or G protein-coupled receptor kinases in response to agonist. This finding is reminiscent to those reported for the internalization of other CKRs including CXCR4 (31-33).



View larger version (34K):
[in this window]
[in a new window]
  		FIGURE 5.
CXCL12 triggers chemotactic signals through RDC1. A, cell surface expression levels of CXCR4 and RDC1 in nucleoporated A0.01 T cells were determined by flow cytometry using the 12G5 anti-CXCR4 or 9C4 anti-RDC1 mAb (red histograms). Nonspecific binding was assessed after incubation of cells with the corresponding isotype-matched control Ab (CTRL; gray histograms) or in the presence of the 9C4 anti-RDC1 (in CXCR4-expressing cells; left section, green histogram) or 12G5 anti-CXCR4 (in RDC1-expressing cells; right panel, green histogram) mAb. A representative experiment of five independent determinations is shown. B, concentration-dependent chemotaxis of A0.01 T-cells expressing either CXCR4 (open bars) or RDC1 (filled bars) is shown in response to CXCL12. C, A0.01 T-cells expressing RDC1 or CXCR4 were treated for 90 min with the indicated Abs and then tested for CXCL12 (10 nM)-induced chemotaxis. D, CXCR4- or RDC1-expressing A0.01 T-cells were assayed for chemotaxis in response to 10 nM CXCL12 or N-terminal truncated CXCL12-(4-67), 30 nM CXCL8, 60 nM CCL21, or 100 nM CXCL13. B-D, results are expressed as the percentage of input A0.01 cells that migrated to the lower chamber and represent the mean ± S.E. of 3-5 independent experiments. The parental A0.01 T cell line was unresponsive to CXCL12. *, p < 0.05; **, p < 0.005 compared with cells that migrated spontaneously (B and D) or in the presence of CXCL12 and the appropriate isotype control Ab (C).

 
CXCL12 Promotes Cell Migration through RDC1—We tested the ability of CXCL12 to trigger chemotaxis of A0.01 T-cells expressing either RDC1 or CXCR4 (Fig. 5A). Addition of the chemokine resulted in a dose-dependent migration of RDC1-positive cells (Fig. 5B). The magnitude of this process was comparable with that of CXCR4-positive cells, with a maximum migration obtained at 10-8 M CXCL12. CXCL12 also triggers chemotactic signal through the truncated {Delta}RDC1 receptor (data not shown), indicating that an intact receptor C terminus is not required for chemotaxis. This finding highlights that the structural determinants required for RDC1-mediated chemotaxis may differ from those involved in receptor internalization, as reported for other CKRs (34, 35). The 9C4 mAb strongly inhibited migration of RDC1-expressing cells but did not modify that of cells expressing CXCR4 (Fig. 5C). Conversely, the anti-CXCR4 12G5 mAb abolished chemotaxis of cells expressing CXCR4 but had no effect on CXCL12-promoted migration of cells expressing RDC1 alone. These results confirm that CXCL12 triggers chemotactic signals directly through RDC1. CCL21, CXCL8, CXCL13 (Fig. 5D), CCL4, RANTES (regulated on activation of normal T cell expressed and secreted)/CCL5 (data not shown), or CXCL12-(4-67) (Fig. 5D) did not promote chemotaxis of RDC1-expressing cells. Taken together, our data indicate that, in cells ectopically expressing RDC1, CXCL12 binds to and signals via RDC1 and further suggest that activation of RDC1 by CXCL12 requires the intact N terminus of the chemokine.

Conclusions—Collectively, our data demonstrate that the orphan receptor RDC1 is a high affinity receptor for CXCL12. Currently, six CXC receptors have been characterized and, according to the nomenclature for CKR families (6), we propose that RDC1 be renamed as CXCR7. The highly conserved sequences of RDC1 and CXCL12 among species suggest that CXCL12/RDC1 interactions may have conserved functional significance. However, the responsiveness of RDC1 to CXCL12 is intriguing because of the nearly identical phenotypes of CXCR4- and CXCL12-deficient mice. The notion that both CXCR4 and CXCL12 knock-out mice die perinatally and display profound defects in hematopoiesis and cerebellar development was generally interpreted as a monogamous relationship between CXCR4 and CXCL12 (36, 37). The interaction between CXCL12 and RDC1 opens questions about the role of this receptor during embryonic life. RDC1 may function in organogenesis and hematopoiesis in concert with CXCR4. Alternatively, but not exclusively, RDC1 may exert distinct activities to those of CXCR4. To this end, it would be important to understand the spatio-temporal regulation and distribution of RDC1 in embryonic tissues.

In post-natal life, as shown for CXCR4, our results are also consistent with a possible role of RDC1 in CXCL12-mediated regulation of CD34+ stem cell homing in the bone marrow and leukocyte trafficking (38-41). Accumulating evidence shows involvement of the CXCL12/CXCR4 axis in inflammatory diseases, tumor metastasis, and angiogenesis (42-45). The reported expression of RDC1 in tumor endothelial cells of brain and peripheral vasculature (46) or in Kaposi's sarcoma-associated herpesvirus dermal microvascular endothelial cells (47) also supports the view that pathological processes might implicate the CXCL12/RDC1 axis.


   FOOTNOTES
 
* This work was supported by Ensemble Contre le SIDA (SIDACTION), INSERM, the Agence Nationale contre le SIDA (ANRS), the Helmut Horten Foundation, and the Swiss National Science Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 Both of these authors contributed equally to this work. Back

2 Supported by a Young Investigator Fellowship from INSERM. Back

3 Supported by fellowships from SIDACTION and ANRS. Back

4 Supported by a scholarship from the Croucher Foundation (Hong Kong). Back

5 To whom correspondence should be addressed: Unité d'Immunologie Virale, Inst. Pasteur, 28 Rue du Dr. Roux, 75015 Paris, France. Tel.: 33-1-40613467; Fax: 33-1-45688941; E-mail: fbachele{at}pasteur.fr.

6 The abbreviations used are: CKR, chemokine receptor; Ab, antibody; biot, biotinylated; FITC, fluorescein isothiocyanate; mAb, monoclonal antibody; PBL, peripheral blood lymphocyte; PBS, phosphate-buffered saline; PE, phycoerythrin; SAv, streptavidin. Back

7 S. Infantino, B. Moepps, and M. Thelen, manuscript in preparation. Back


   ACKNOWLEDGMENTS
 
We thank L. Klemm (Unité d'Immunologie Virale, Institut Pasteur, Paris, France) for technical help and are grateful to P. Charneau (Unité de Virologie Moléculaire et de Vectorologie, Institut Pasteur, Paris, France) and F. Baleux (Unité de Chimie Organique, Institut Pasteur, Paris, France) for providing us the pTRIP vector and the chemokines CXCL12, CXCL12-(4-67), and biot-CXCL12, respectively.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS AND DISCUSSION
 REFERENCES
 

  1. Nelson, P. J., and Krensky, A. M. (2001) Immunity 14, 377-386[CrossRef][Medline] [Order article via Infotrieve]
  2. Campbell, D. J., Kim, C. H., and Butcher, E. C. (2003) Immunol. Rev. 195, 58-71[CrossRef][Medline] [Order article via Infotrieve]
  3. Moser, B., Wolf, M., Walz, A., and Loetscher, P. (2004) Trends Immunol. 25, 75-84[CrossRef][Medline] [Order article via Infotrieve]
  4. Zlotnik, A., and Yoshie, O. (2000) Immunity 12, 121-127[CrossRef][Medline] [Order article via Infotrieve]
  5. Loetscher, P., and Clark-Lewis, I. (2001) J. Leukocyte Biol. 69, 881-884[Abstract/Free Full Text]
  6. Murphy, P. M., Baggiolini, M., Charo, I. F., Hebert, C. A., Horuk, R., Matsushima, K., Miller, L. H., Oppenheim, J. J., and Power, C. A. (2000) Pharmacol. Rev. 52, 145-176[Abstract/Free Full Text]
  7. Libert, F., Parmentier, M., Lefort, A., Dinsart, C., Van Sande, J., Maenhaut, C., Simons, M. J., Dumont, J. E., and Vassart, G. (1989) Science 244, 569-572[Abstract/Free Full Text]
  8. Libert, F., Parmentier, M., Lefort, A., Dumont, J. E., and Vassart, G. (1990) Nucleic Acids Res. 18, 1917[Free Full Text]
  9. Sreedharan, S. P., Robichon, A., Peterson, K. E., and Goetzl, E. J. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 4986-4990[Abstract/Free Full Text]
  10. Nagata, S., Ishihara, T., Robberecht, P., Libert, F., Parmentier, M., Christophe, J., and Vassart, G. (1992) Trends Pharmacol. Sci. 13, 102-103[CrossRef][Medline] [Order article via Infotrieve]
  11. Cook, J. S., Wolsing, D. H., Lameh, J., Olson, C. A., Correa, P. E., Sadee, W., Blumenthal, E. M., and Rosenbaum, J. S. (1992) FEBS Lett. 300, 149-152[CrossRef][Medline] [Order article via Infotrieve]
  12. Heesen, M., Berman, M. A., Charest, A., Housman, D., Gerard, C., and Dorf, M. E. (1998) Immunogenetics 47, 364-370[CrossRef][Medline] [Order article via Infotrieve]
  13. Joost, P., and Methner, A. (2002) Genome Biol. http://genomebiology.com/2002/3/11/research/0063
  14. Fredriksson, R., Lagerstrom, M. C., Lundin, L. G., and Schioth, H. B. (2003) Mol. Pharmacol. 63, 1256-1272[Abstract/Free Full Text]
  15. Libert, F., Passage, E., Parmentier, M., Simons, M. J., Vassart, G., and Mattei, M. G. (1991) Genomics 11, 225-227[CrossRef][Medline] [Order article via Infotrieve]
  16. Ahuja, S. K., Ozcelik, T., Milatovitch, A., Francke, U., and Murphy, P. M. (1992) Nat. Genet. 2, 31-36[Medline] [Order article via Infotrieve]
  17. Shimizu, N., Soda, Y., Kanbe, K., Liu, H. Y., Mukai, R., Kitamura, T., and Hoshino, H. (2000) J. Virol. 74, 619-626[Abstract/Free Full Text]
  18. Shimizu, N., and Gojobori, T. (2000) Gene 259, 199-205[CrossRef][Medline] [Order article via Infotrieve]
  19. Balabanian, K., Harriague, J., Decrion, C., Lagane, B., Shorte, S., Baleux, F., Virelizier, J. L., Arenzana-Seisdedos, F., and Chakrabarti, L. A. (2004) J. Immunol. 173, 7150-7160[Abstract/Free Full Text]
  20. Balabanian, K., Lagane, B., Pablos, J. L., Laurent, L., Planchenault, T., Verola, O., Lebbe, C., Kerob, D., Dupuy, A., Hermine, O., Nicolas, J. F., Latger-Cannard, V., Bensoussan, D., Bordigoni, P., Baleux, F., Le Deist, F., Virelizier, J. L., Arenzana-Seisdedos, F., and Bachelerie, F. (2005) Blood 105, 2449-2457[Medline] [Order article via Infotrieve]
  21. Brelot, A., Heveker, N., Montes, M., and Alizon, M. (2000) J. Biol. Chem. 275, 23736-23744[Abstract/Free Full Text]
  22. Eva, C., and Sprengel, R. (1993) DNA Cell Biol. 12, 393-399[Medline] [Order article via Infotrieve]
  23. Endres, M. J., Clapham, P. R., Marsh, M., Ahuja, M., Turner, J. D., McKnight, A., Thomas, J. F., Stoebenau-Haggarty, B., Choe, S., Vance, P. J., Wells, T. N., Power, C. A., Sutterwala, S. S., Doms, R. W., Landau, N. R., and Hoxie, J. A. (1996) Cell 87, 745-756[CrossRef][Medline] [Order article via Infotrieve]
  24. Brelot, A., Heveker, N., Pleskoff, O., Sol, N., and Alizon, M. (1997) J. Virol. 71, 4744-4751[Abstract]
  25. Brelot, A., Heveker, N., Adema, K., Hosie, M. J., Willett, B., Alizon, M., Pleskoff, O., and Sol, N. (1999) J. Virol. 73, 2576-2586[Abstract/Free Full Text]
  26. Farzan, M., Mirzabekov, T., Kolchinsky, P., Wyatt, R., Cayabyab, M., Gerard, N. P., Gerard, C., Sodroski, J., and Choe, H. (1999) Cell 96, 667-676[CrossRef][Medline] [Order article via Infotrieve]
  27. Crump, M. P., Gong, J. H., Loetscher, P., Rajarathnam, K., Amara, A., Arenzana-Seisdedos, F., Virelizier, J. L., Baggiolini, M., Sykes, B. D., and Clark-Lewis, I. (1997) EMBO J. 16, 6996-7007[CrossRef][Medline] [Order article via Infotrieve]
  28. Valenzuela-Fernandez, A., Planchenault, T., Baleux, F., Staropoli, I., Le-Barillec, K., Leduc, D., Delaunay, T., Lazarini, F., Virelizier, J. L., Chignard, M., Pidard, D., and Arenzana-Seisdedos, F. (2002) J. Biol. Chem. 277, 15677-15689[Abstract/Free Full Text]
  29. Thelen, M. (2001) Nat. Immunol. 2, 129-134[CrossRef][Medline] [Order article via Infotrieve]
  30. Lefkowitz, R. J., and Shenoy, S. K. (2005) Science 308, 512-517[Abstract/Free Full Text]
  31. Signoret, N., Oldridge, J., Pelchen-Matthews, A., Klasse, P. J., Tran, T., Brass, L. F., Rosenkilde, M. M., Schwartz, T. W., Holmes, W., Dallas, W., Luther, M. A., Wells, T. N., Hoxie, J. A., and Marsh, M. (1997) J. Cell Biol. 139, 651-664[Abstract/Free Full Text]
  32. Amara, A., Gall, S. L., Schwartz, O., Salamero, J., Montes, M., Loetscher, P., Baggiolini, M., Virelizier, J. L., and Arenzana-Seisdedos, F. (1997) J. Exp. Med. 186, 139-146[Abstract/Free Full Text]
  33. Haribabu, B., Richardson, R. M., Fisher, I., Sozzani, S., Peiper, S. C., Horuk, R., Ali, H., and Snyderman, R. (1997) J. Biol. Chem. 272, 28726-28731[Abstract/Free Full Text]
  34. Venkatesan, S., Petrovic, A., Locati, M., Kim, Y. O., Weissman, D., and Murphy, P. M. (2001) J. Biol. Chem. 276, 40133-40145[Abstract/Free Full Text]
  35. Lagane, B., Ballet, S., Planchenault, T., Balabanian, K., Le Poul, E., Blanpain, C., Percherancier, Y., Staropoli, I., Vassart, G., Oppermann, M., Parmentier, M., and Bachelerie, F. (2005) Mol. Pharmacol. 67, 1966-1976[Abstract/Free Full Text]
  36. Zou, Y. R., Kottmann, A. H., Kuroda, M., Taniuchi, I., and Littman, D. R. (1998) Nature 393, 595-599[CrossRef][Medline] [Order article via Infotrieve]
  37. Ma, Q., Jones, D., Borghesani, P. R., Segal, R. A., Nagasawa, T., Kishimoto, T., Bronson, R. T., and Springer, T. A. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 9448-9453[Abstract/Free Full Text]
  38. Peled, A., Petit, I., Kollet, O., Magid, M., Ponomaryov, T., Byk, T., Nagler, A., Ben-Hur, H., Many, A., Shultz, L., Lider, O., Alon, R., Zipori, D., and Lapidot, T. (1999) Science 283, 845-848[Abstract/Free Full Text]
  39. Petit, I., Szyper-Kravitz, M., Nagler, A., Lahav, M., Peled, A., Habler, L., Ponomaryov, T., Taichman, R. S., Arenzana-Seisdedos, F., Fujii, N., Sandbank, J., Zipori, D., and Lapidot, T. (2002) Nat. Immunol. 3, 687-694[CrossRef][Medline] [Order article via Infotrieve]
  40. Okada, T., Ngo, V. N., Ekland, E. H., Forster, R., Lipp, M., Littman, D. R., and Cyster, J. G. (2002) J. Exp. Med. 196, 65-75[Abstract/Free Full Text]
  41. Martin, C., Burdon, P. C., Bridger, G., Gutierrez-Ramos, J. C., Williams, T. J., and Rankin, S. M. (2003) Immunity 19, 583-593[CrossRef][Medline] [Order article via Infotrieve]
  42. Buckley, C. D., Amft, N., Bradfield, P. F., Pilling, D., Ross, E., Arenzana-Seisdedos, F., Amara, A., Curnow, S. J., Lord, J. M., Scheel-Toellner, D., and Salmon, M. (2000) J. Immunol. 165, 3423-3429[Abstract/Free Full Text]
  43. Lukacs, N. W., Berlin, A., Schols, D., Skerlj, R. T., and Bridger, G. J. (2002) Am. J. Pathol. 160, 1353-1360[Abstract/Free Full Text]
  44. Epstein, R. J. (2004) Nat. Rev. Cancer 4, 901-909[CrossRef][Medline] [Order article via Infotrieve]
  45. Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., and Weinberg, R. A. (2005) Cell 121, 335-348[CrossRef][Medline] [Order article via Infotrieve]
  46. Madden, S. L., Cook, B. P., Nacht, M., Weber, W. D., Callahan, M. R., Jiang, Y., Dufault, M. R., Zhang, X., Zhang, W., Walter-Yohrling, J., Rouleau, C., Akmaev, V. R., Wang, C. J., Cao, X., St Martin, T. B., Roberts, B. L., Teicher, B. A., Klinger, K. W., Stan, R. V., Lucey, B., Carson-Walter, E. B., Laterra, J., and Walter, K. A. (2004) Am. J. Pathol. 165, 601-608[Abstract/Free Full Text]
  47. Raggo, C., Ruhl, R., McAllister, S., Koon, H., Dezube, B. J., Fruh, K., and Moses, A. V. (2005) Cancer Res. 65, 5084-5095[Abstract/Free Full Text]
  48. Moepps, B., Nuesseler, E., Braun, M., and Gierschik, P. (2005) Mol. Immunol., in press

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
A. Levoye, K. Balabanian, F. Baleux, F. Bachelerie, and B. Lagane
CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling
Blood, June 11, 2009; 113(24): 6085 - 6093.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
I. Kalatskaya, Y. A. Berchiche, S. Gravel, B. J. Limberg, J. S. Rosenbaum, and N. Heveker
AMD3100 Is a CXCR7 Ligand with Allosteric Agonist Properties
Mol. Pharmacol., May 1, 2009; 75(5): 1240 - 1247.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
E. Raz and H. Mahabaleshwar
Chemokine signaling in embryonic cell migration: a fisheye view
Development, April 15, 2009; 136(8): 1223 - 1229.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
H. Gao, W. Priebe, J. Glod, and D. Banerjee
Activation of Signal Transducers and Activators of Transcription 3 and Focal Adhesion Kinase by Stromal Cell-Derived Factor 1 Is Required for Migration of Human Mesenchymal Stem Cells in Response to Tumor Cell-Conditioned Medium
Stem Cells, April 1, 2009; 27(4): 857 - 865.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Augsten, C. Hagglof, E. Olsson, C. Stolz, P. Tsagozis, T. Levchenko, M. J. Frederick, A. Borg, P. Micke, L. Egevad, et al.
CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth
PNAS, March 3, 2009; 106(9): 3414 - 3419.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
K. E. Luker, M. Gupta, and G. D. Luker
Imaging chemokine receptor dimerization with firefly luciferase complementation
FASEB J, March 1, 2009; 23(3): 823 - 834.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. A. Mines, J. S. Goodwin, L. E. Limbird, F.-F. Cui, and G.-H. Fan
Deubiquitination of CXCR4 by USP14 Is Critical for Both CXCL12-induced CXCR4 Degradation and Chemotaxis but Not ERK Activation
J. Biol. Chem., February 27, 2009; 284(9): 5742 - 5752.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
N. P. Smirnova, A. A. Ptitsyn, K. J. Austin, H. Bielefeldt-Ohmann, H. Van Campen, H. Han, A. L. van Olphen, and T. R. Hansen
Persistent fetal infection with bovine viral diarrhea virus differentially affects maternal blood cell signal transduction pathways
Physiol Genomics, February 2, 2009; 36(3): 129 - 139.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Struyf, S. Noppen, T. Loos, A. Mortier, M. Gouwy, H. Verbeke, D. Huskens, S. Luangsay, M. Parmentier, K. Geboes, et al.
Citrullination of CXCL12 Differentially Reduces CXCR4 and CXCR7 Binding with Loss of Inflammatory and Anti-HIV-1 Activity via CXCR4
J. Immunol., January 1, 2009; 182(1): 666 - 674.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
S. N. Zaman, M. E. Resek, and S. M. Robbins
Dual acylation and lipid raft association of Src-family protein tyrosine kinases are required for SDF-1/CXCL12-mediated chemotaxis in the Jurkat human T cell lymphoma cell line
J. Leukoc. Biol., October 1, 2008; 84(4): 1082 - 1091.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
T. N. Hartmann, V. Grabovsky, R. Pasvolsky, Z. Shulman, E. C. Buss, A. Spiegel, A. Nagler, T. Lapidot, M. Thelen, and R. Alon
A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells
J. Leukoc. Biol., October 1, 2008; 84(4): 1130 - 1140.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
J. Ben-Shoshan, S. Schwartz, G. Luboshits, S. Maysel-Auslender, A. Barzelay, S. Polak-Charcon, E. Tzahor, I. Barshack, A. Barak, H. Levkovitch-Verbin, et al.
Constitutive Expression of HIF-1{alpha} and HIF-2{alpha} in Bone Marrow Stromal Cells Differentially Promotes Their Proangiogenic Properties
Stem Cells, October 1, 2008; 26(10): 2634 - 2643.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
A. E. Cardona, M. Li, L. Liu, C. Savarin, and R. M. Ransohoff
Chemokines in and out of the central nervous system: much more than chemotaxis and inflammation
J. Leukoc. Biol., September 1, 2008; 84(3): 587 - 594.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Hachet-Haas, K. Balabanian, F. Rohmer, F. Pons, C. Franchet, S. Lecat, K. Y. C. Chow, R. Dagher, P. Gizzi, B. Didier, et al.
Small Neutralizing Molecules to Inhibit Actions of the Chemokine CXCL12
J. Biol. Chem., August 22, 2008; 283(34): 23189 - 23199.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
Z. Sameermahmood, M. Balasubramanyam, T. Saravanan, and M. Rema
Curcumin Modulates SDF-1{alpha}/CXCR4-Induced Migration of Human Retinal Endothelial Cells (HRECs)
Invest. Ophthalmol. Vis. Sci., August 1, 2008; 49(8): 3305 - 3311.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
W. Lucchesi, G. Brady, O. Dittrich-Breiholz, M. Kracht, R. Russ, and P. J. Farrell
Differential Gene Regulation by Epstein-Barr Virus Type 1 and Type 2 EBNA2
J. Virol., August 1, 2008; 82(15): 7456 - 7466.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
C. M. Costello, K. Howell, E. Cahill, J. McBryan, M. Konigshoff, O. Eickelberg, S. Gaine, F. Martin, and P. McLoughlin
Lung-selective gene responses to alveolar hypoxia: potential role for the bone morphogenetic antagonist gremlin in pulmonary hypertension
Am J Physiol Lung Cell Mol Physiol, August 1, 2008; 295(2): L272 - L284.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. O. Rehman and C.-Y. Wang
SDF-1{alpha} Promotes Invasion of Head and Neck Squamous Cell Carcinoma by Activating NF-{kappa}B
J. Biol. Chem., July 18, 2008; 283(29): 19888 - 19894.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
L. C. Edman, H. Mira, A. Erices, S. Malmersjo, E. Andersson, P. Uhlen, and E. Arenas
{alpha}-Chemokines Regulate Proliferation, Neurogenesis, and Dopaminergic Differentiation of Ventral Midbrain Precursors and Neurospheres
Stem Cells, July 1, 2008; 26(7): 1891 - 1900.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Lagane, K. Y. C. Chow, K. Balabanian, A. Levoye, J. Harriague, T. Planchenault, F. Baleux, N. Gunera-Saad, F. Arenzana-Seisdedos, and F. Bachelerie
CXCR4 dimerization and {beta}-arrestin-mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome
Blood, July 1, 2008; 112(1): 34 - 44.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
N. Smart and P. R. Riley
The Stem Cell Movement
Circ. Res., May 23, 2008; 102(10): 1155 - 1168.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. K. Williams, M. Segarra, M. De La Luz Sierra, R. C.A. Sainson, G. Tosato, and A. L. Harris
Regulation of CXCR4 by the Notch Ligand Delta-like 4 in Endothelial Cells
Cancer Res., March 15, 2008; 68(6): 1889 - 1895.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Wang, Y. Shiozawa, J. Wang, Y. Wang, Y. Jung, K. J. Pienta, R. Mehra, R. Loberg, and R. S. Taichman
The Role of CXCR7/RDC1 as a Chemokine Receptor for CXCL12/SDF-1 in Prostate Cancer
J. Biol. Chem., February 15, 2008; 283(7): 4283 - 4294.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
J. Sainz and M. Sata
Open Sesame!: CXCR4 Blockade Recruits Neutrophils Into the Plaque
Circ. Res., February 1, 2008; 102(2): 154 - 156.
[Full Text] [PDF]

Home page
 DiabetesHome page
C. D. Sharp, M. Huang, J. Glawe, D. R. Patrick, S. Pardue, S. C. Barlow, and C. G. Kevil
Stromal Cell Derived Factor-1/CXCL12 Stimulates Chemorepulsion of NOD/LtJ T-Cell Adhesion to Islet Microvascular Endothelium
Diabetes, January 1, 2008; 57(1): 102 - 112.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
V. Odemis, K. Boosmann, M. T. Dieterlen, and J. Engele
The chemokine SDF1 controls multiple steps of myogenesis through atypical PKC{zeta}
J. Cell Sci., November 15, 2007; 120(22): 4050 - 4059.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
R. Lima e Silva, J. Shen, S. F. Hackett, S. Kachi, H. Akiyama, K. Kiuchi, K. Yokoi, M. C. Hatara, T. Lauer, S. Aslam, et al.
The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization
FASEB J, October 1, 2007; 21(12): 3219 - 3230.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
F. Sierro, C. Biben, L. Martinez-Munoz, M. Mellado, R. M. Ransohoff, M. Li, B. Woehl, H. Leung, J. Groom, M. Batten, et al.
Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7
PNAS, September 11, 2007; 104(37): 14759 - 14764.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. C. Hirbe, J. Rubin, O. Uluckan, E. A. Morgan, M. C. Eagleton, J. L. Prior, D. Piwnica-Worms, and K. N. Weilbaecher
Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone
PNAS, August 28, 2007; 104(35): 14062 - 14067.
[Abstract] [Full Text] [PDF]

Home page
 Sci SignalHome page
J. R. Perlin and W. S. Talbot
Signals on the Move: Chemokine Receptors and Organogenesis in Zebrafish
Sci. Signal., August 21, 2007; 2007(400): pe45 - pe45.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
J. D. Altenburg, H. E. Broxmeyer, Q. Jin, S. Cooper, S. Basu, and G. Alkhatib
A Naturally Occurring Splice Variant of CXCL12/Stromal Cell-Derived Factor 1 Is a Potent Human Immunodeficiency Virus Type 1 Inhibitor with Weak Chemotaxis and Cell Survival Activities
J. Virol., August 1, 2007; 81(15): 8140 - 8148.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
N. Miyasaka, H. Knaut, and Y. Yoshihara
Cxcl12/Cxcr4 chemokine signaling is required for placode assembly and sensory axon pathfinding in the zebrafish olfactory system
Development, July 1, 2007; 134(13): 2459 - 2468.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Proost, A. Mortier, T. Loos, J. Vandercappellen, M. Gouwy, I. Ronsse, E. Schutyser, W. Put, M. Parmentier, S. Struyf, et al.
Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration
Blood, July 1, 2007; 110(1): 37 - 44.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W. Zhu, O. Boachie-Adjei, B. A. Rawlins, B. Frenkel, A. L. Boskey, L. B. Ivashkiv, and C. P. Blobel
A Novel Regulatory Role for Stromal-derived Factor-1 Signaling in Bone Morphogenic Protein-2 Osteogenic Differentiation of Mesenchymal C2C12 Cells
J. Biol. Chem., June 29, 2007; 282(26): 18676 - 18685.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
S. Hatse, D. Huskens, K. Princen, K. Vermeire, G. J. Bridger, E. De Clercq, M. M. Rosenkilde, T. W. Schwartz, and D. Schols
Modest Human Immunodeficiency Virus Coreceptor Function of CXCR3 Is Strongly Enhanced by Mimicking the CXCR4 Ligand Binding Pocket in the CXCR3 Receptor
J. Virol., April 1, 2007; 81(7): 3632 - 3639.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Alsayed, H. Ngo, J. Runnels, X. Leleu, U. K. Singha, C. M. Pitsillides, J. A. Spencer, T. Kimlinger, J. M. Ghobrial, X. Jia, et al.
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma
Blood, April 1, 2007; 109(7): 2708 - 2717.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
A. Guyon and J.-L. Nahon
Multiple actions of the chemokine stromal cell-derived factor-1{alpha} on neuronal activity
J. Mol. Endocrinol., March 1, 2007; 38(3): 365 - 376.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. R. Harvey, P. Mellor, H. Eldaly, T. W.J. Lennard, J. A. Kirby, and S. Ali
Inhibition of CXCR4-Mediated Breast Cancer Metastasis: A Potential Role for Heparinoids?
Clin. Cancer Res., March 1, 2007; 13(5): 1562 - 1570.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
I. Kryczek, S. Wei, E. Keller, R. Liu, and W. Zou
Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis
Am J Physiol Cell Physiol, March 1, 2007; 292(3): C987 - C995.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
V. Svetic, G. E. Hollway, S. Elworthy, T. R. Chipperfield, C. Davison, R. J. Adams, J. S. Eisen, P. W. Ingham, P. D. Currie, and R. N. Kelsh
Sdf1a patterns zebrafish melanophores and links the somite and melanophore pattern defects in choker mutants
Development, March 1, 2007; 134(5): 1011 - 1022.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
A. Segret, C. Rucker-Martin, C. Pavoine, J. Flavigny, E. Deroubaix, M.-A. Chatel, A. Lombet, and J.-F. Renaud
Structural Localization and Expression of CXCL12 and CXCR4 in Rat Heart and Isolated Cardiac Myocytes
J. Histochem. Cytochem., February 1, 2007; 55(2): 141 - 150.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
G. C. Schatteman, M. Dunnwald, and C. Jiao
Biology of bone marrow-derived endothelial cell precursors
Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H1 - H18.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. Vergote, G. S. Butler, M. Ooms, J. H. Cox, C. Silva, M. D. Hollenberg, J. H. Jhamandas, C. M. Overall, and C. Power
Proteolytic processing of SDF-1{alpha} reveals a change in receptor specificity mediating HIV-associated neurodegeneration
PNAS, December 12, 2006; 103(50): 19182 - 19187.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Li, C. Luo, M. Mines, J. Zhang, and G.-H. Fan
Chemokine CXCL12 Induces Binding of Ferritin Heavy Chain to the Chemokine Receptor CXCR4, Alters CXCR4 Signaling, and Induces Phosphorylation and Nuclear Translocation of Ferritin Heavy Chain
J. Biol. Chem., December 8, 2006; 281(49): 37616 - 37627.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
J. M. Burns, B. C. Summers, Y. Wang, A. Melikian, R. Berahovich, Z. Miao, M. E. T. Penfold, M. J. Sunshine, D. R. Littman, C. J. Kuo, et al.
A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development
J. Exp. Med., September 4, 2006; 203(9): 2201 - 2213.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. N. Ajuebor, J. A. Carey, and M. G. Swain
CCR5 in T Cell-Mediated Liver Diseases: What's Going On?
J. Immunol., August 15, 2006; 177(4): 2039 - 2045.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. C. Bosco, M. Puppo, C. Santangelo, L. Anfosso, U. Pfeffer, P. Fardin, F. Battaglia, and L. Varesio
Hypoxia Modifies the Transcriptome of Primary Human Monocytes: Modulation of Novel Immune-Related Genes and Identification Of CC-Chemokine Ligand 20 as a New Hypoxia-Inducible Gene
J. Immunol., August 1, 2006; 177(3): 1941 - 1955.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
J. P. Luyendyk, L. D. Lehman-McKeeman, D. M. Nelson, V. M. Bhaskaran, T. P. Reilly, B. D. Car, G. H. Cantor, J. F. Maddox, P. E. Ganey, and R. A. Roth
Unique Gene Expression and Hepatocellular Injury in the Lipopolysaccharide-Ranitidine Drug Idiosyncrasy Rat Model: Comparison with Famotidine
Toxicol. Sci., April 1, 2006; 90(2): 569 - 585.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Foudi, P. Jarrier, Y. Zhang, M. Wittner, J.-F. Geay, Y. Lecluse, T. Nagasawa, W. Vainchenker, and F. Louache
Reduced retention of radioprotective hematopoietic cells within the bone marrow microenvironment in CXCR4-/- chimeric mice
Blood, March 15, 2006; 107(6): 2243 - 2251.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Infantino, B. Moepps, and M. Thelen
Expression and Regulation of the Orphan Receptor RDC1 and Its Putative Ligand in Human Dendritic and B Cells
J. Immunol., February 15, 2006; 176(4): 2197 - 2207.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
B. Zhao, S. Maruo, A. Cooper, M. R. Chase, E. Johannsen, E. Kieff, and E. Cahir-McFarland
RNAs induced by Epstein-Barr virus nuclear antigen 2 in lymphoblastoid cell lines
PNAS, February 7, 2006; 103(6): 1900 - 1905.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/42/35760    most recent
M508234200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Balabanian, K.
Right arrow Articles by Bachelerie, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Balabanian, K.
Right arrow Articles by Bachelerie, F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement